CY1124146T1 - Συστηματα εκφρασης - Google Patents
Συστηματα εκφρασηςInfo
- Publication number
- CY1124146T1 CY1124146T1 CY20211100421T CY211100421T CY1124146T1 CY 1124146 T1 CY1124146 T1 CY 1124146T1 CY 20211100421 T CY20211100421 T CY 20211100421T CY 211100421 T CY211100421 T CY 211100421T CY 1124146 T1 CY1124146 T1 CY 1124146T1
- Authority
- CY
- Cyprus
- Prior art keywords
- expression system
- protein
- polynucleotide
- stimulates
- encodes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/007995 WO2012089231A1 (en) | 2010-12-30 | 2010-12-30 | Paramyxovirus vaccines |
| EP11805889.0A EP2658573B1 (en) | 2010-12-30 | 2011-12-30 | Expression systems |
| PCT/EP2011/074307 WO2012089833A2 (en) | 2010-12-30 | 2011-12-30 | Expression Systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124146T1 true CY1124146T1 (el) | 2022-05-27 |
Family
ID=45464575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100421T CY1124146T1 (el) | 2010-12-30 | 2021-05-17 | Συστηματα εκφρασης |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20140141042A1 (https=) |
| EP (2) | EP2658573B1 (https=) |
| JP (2) | JP6324725B2 (https=) |
| KR (1) | KR102070463B1 (https=) |
| CN (1) | CN103442731B (https=) |
| AU (2) | AU2011351380A1 (https=) |
| BR (1) | BR112013016823A2 (https=) |
| CA (1) | CA2821111A1 (https=) |
| CY (1) | CY1124146T1 (https=) |
| DK (1) | DK2658573T3 (https=) |
| ES (1) | ES2869199T3 (https=) |
| HR (1) | HRP20210750T1 (https=) |
| HU (1) | HUE053986T2 (https=) |
| IL (1) | IL226551B (https=) |
| LT (1) | LT2658573T (https=) |
| MX (1) | MX352205B (https=) |
| NZ (1) | NZ610743A (https=) |
| PL (1) | PL2658573T3 (https=) |
| PT (1) | PT2658573T (https=) |
| RU (1) | RU2609645C2 (https=) |
| SG (2) | SG10201510760WA (https=) |
| SI (1) | SI2658573T1 (https=) |
| WO (2) | WO2012089231A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3842068A1 (en) | 2012-07-05 | 2021-06-30 | GlaxoSmithKline Biologicals S.A. | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| DK2879702T3 (da) * | 2012-08-01 | 2020-02-24 | Bavarian Nordic As | Rekombinant modificeret vacciniavirus ankara (mva)-vaccine mod respiratorisk syncytialvirus (rsv) |
| KR102435054B1 (ko) * | 2012-08-01 | 2022-08-22 | 버베리안 노딕 에이/에스 | 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신 |
| US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| AU2013301312A1 (en) | 2012-08-06 | 2015-03-19 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against RSV and B. pertussis |
| CA2900110A1 (en) * | 2013-02-01 | 2014-08-07 | Medimmune, Llc | Respiratory syncytial virus f protein epitopes |
| US20140286981A1 (en) | 2013-03-14 | 2014-09-25 | Wisconsin Alumni Research Foundation | Broadly reactive mosaic peptide for influenza vaccine |
| EP3653701A1 (en) | 2013-03-15 | 2020-05-20 | The Research Foundation for The State University of New York | Attenuated influenza viruses and vaccines |
| MX2016001695A (es) | 2013-08-05 | 2016-05-02 | Glaxosmithkline Biolog Sa | Composiciones inmunogenas de combinacion. |
| MX384992B (es) | 2014-06-13 | 2025-03-14 | Glaxosmithkline Biologicals Sa | Combinaciones inmunógenas. |
| BR112017026523A2 (pt) | 2015-06-12 | 2018-08-14 | Glaxosmithkline Biologicals Sa | vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado. |
| EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| GB201614485D0 (en) | 2016-08-25 | 2016-10-12 | Univ Oxford Innovation Ltd | Immunogenic composition |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| WO2018107088A2 (en) | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| ES2959811T3 (es) | 2016-12-09 | 2024-02-28 | Glaxosmithkline Biologicals Sa | Construcciones de adenovirus de chimpancé con antígenos de Lyssavirus |
| GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
| GB201701239D0 (en) | 2017-01-25 | 2017-03-08 | Glaxosmithkline Biologicals Sa | Novel formulation |
| CN107119064A (zh) * | 2017-02-21 | 2017-09-01 | 南京农业大学 | 重组枯草芽孢杆菌串联表达禽流感病毒ha抗原片段和pb1－f2蛋白 |
| EP3697902A1 (en) | 2017-10-16 | 2020-08-26 | GlaxoSmithKline Biologicals S.A. | Enhanced promoter |
| EP3697919A1 (en) | 2017-10-16 | 2020-08-26 | GlaxoSmithKline Biologicals SA | Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof |
| JP2021500880A (ja) | 2017-10-16 | 2021-01-14 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ２つの発現カセットを有するサルアデノウイルスベクター |
| AU2018356538B2 (en) * | 2017-10-25 | 2023-09-28 | Nouscom Ag | Eukaryotic cell line |
| BR112020012361A2 (pt) | 2017-12-20 | 2020-11-24 | Glaxosmithkline Biologicals S.A. | constructos de antígeno do vírus epstein-barr |
| EP3807298A1 (en) | 2018-06-12 | 2021-04-21 | GlaxoSmithKline Biologicals S.A. | Adenovirus polynucleotides and polypeptides |
| WO2020014656A1 (en) * | 2018-07-13 | 2020-01-16 | University Of Georgia Research Foundation | Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof |
| CN109180820B (zh) * | 2018-09-19 | 2021-06-25 | 天康生物制药有限公司 | 马流感病毒h3n8亚型的融合蛋白及其制备方法、应用和疫苗 |
| WO2020061443A2 (en) * | 2018-09-21 | 2020-03-26 | Board Of Regents Of The University Of Nebraska | Methods of making and using universal centralized influenza vaccine genes |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| CN112220921B (zh) * | 2020-08-25 | 2022-08-16 | 北京交通大学 | 一种针对呼吸道合胞病毒感染的组合疫苗 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7135312B2 (en) * | 1993-04-15 | 2006-11-14 | University Of Rochester | Circular DNA vectors for synthesis of RNA and DNA |
| DE19651443A1 (de) * | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
| US7655774B2 (en) | 2000-02-18 | 2010-02-02 | University Of Washington | Ancestral and COT viral sequences, proteins and immunogenic compositions |
| US20040096451A1 (en) * | 2002-07-25 | 2004-05-20 | Young James F. | Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies |
| EP1441762A1 (en) * | 2001-09-28 | 2004-08-04 | University Of South Florida | Rsv gene expression vaccine |
| AU2002365366B2 (en) * | 2001-11-21 | 2007-05-10 | The Trustees Of The University Of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| EP1485468A4 (en) * | 2002-02-21 | 2007-01-03 | Medimmune Vaccines Inc | RECOMBINANT PARAIN FLUENZAVIRUS EXPRESSION SYSTEMS AND VACCINES WITH ANTIGENS FROM METAPNEUMOVIRUS STEM-RELATED HETEROLOGISTS |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| US7566458B2 (en) * | 2003-06-16 | 2009-07-28 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
| DE602005017743D1 (de) | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| WO2007126887A2 (en) * | 2006-03-27 | 2007-11-08 | The Government Of The United States Of America | Immunogenic compositions comprising polynucleotides encoding matrix protein 2 and methods of use |
| WO2008054540A2 (en) * | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| AU2007345319B2 (en) * | 2006-07-13 | 2012-09-06 | Institute For Advanced Study | Viral inhibitory nucleotide sequences and vaccines |
| DE202007018643U1 (de) | 2006-09-05 | 2009-01-02 | BSH Bosch und Siemens Hausgeräte GmbH | Bodendüse für Hartböden |
| WO2008133663A2 (en) * | 2006-11-30 | 2008-11-06 | Government Of The United States Of America, As Represented By The Secretary, | Codon modified immunogenic compositions and methods of use |
| WO2009092113A2 (en) * | 2008-01-19 | 2009-07-23 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the delivery of vaccines to disrupted epithelium |
| US20100040650A1 (en) * | 2008-05-30 | 2010-02-18 | Crowe Jr James E | Virus-Like paramyxovirus particles and vaccines |
| WO2009146902A1 (en) * | 2008-06-03 | 2009-12-10 | Okairòs Ag | A vaccine for the prevention and therapy of hcv infections |
| JP5781929B2 (ja) * | 2008-07-15 | 2015-09-24 | ノバルティス アーゲー | 免疫原性の両親媒性ペプチド組成物 |
| WO2010077712A1 (en) * | 2008-12-09 | 2010-07-08 | Novavax, Inc. | Bovine respiratory syncytial virus virus-like particle (vlps) |
| PL2370099T3 (pl) * | 2008-12-09 | 2016-10-31 | Zmodyfikowane białka F RSV i sposoby ich zastosowania | |
| JP2010168288A (ja) * | 2009-01-20 | 2010-08-05 | Yokohama City Univ | 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強 |
| PL2391638T3 (pl) | 2009-02-02 | 2018-11-30 | Glaxosmithkline Biologicals Sa | Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania |
-
2010
- 2010-12-30 WO PCT/EP2010/007995 patent/WO2012089231A1/en not_active Ceased
-
2011
- 2011-12-30 SG SG10201510760WA patent/SG10201510760WA/en unknown
- 2011-12-30 RU RU2013135498A patent/RU2609645C2/ru active
- 2011-12-30 BR BR112013016823A patent/BR112013016823A2/pt not_active IP Right Cessation
- 2011-12-30 MX MX2013007716A patent/MX352205B/es active IP Right Grant
- 2011-12-30 LT LTEP11805889.0T patent/LT2658573T/lt unknown
- 2011-12-30 CA CA2821111A patent/CA2821111A1/en active Pending
- 2011-12-30 SI SI201131973T patent/SI2658573T1/sl unknown
- 2011-12-30 EP EP11805889.0A patent/EP2658573B1/en active Active
- 2011-12-30 AU AU2011351380A patent/AU2011351380A1/en not_active Abandoned
- 2011-12-30 KR KR1020137017082A patent/KR102070463B1/ko not_active Expired - Fee Related
- 2011-12-30 NZ NZ610743A patent/NZ610743A/en not_active IP Right Cessation
- 2011-12-30 ES ES11805889T patent/ES2869199T3/es active Active
- 2011-12-30 SG SG2013041348A patent/SG190919A1/en unknown
- 2011-12-30 WO PCT/EP2011/074307 patent/WO2012089833A2/en not_active Ceased
- 2011-12-30 HR HRP20210750TT patent/HRP20210750T1/hr unknown
- 2011-12-30 JP JP2013546722A patent/JP6324725B2/ja not_active Expired - Fee Related
- 2011-12-30 DK DK11805889.0T patent/DK2658573T3/da active
- 2011-12-30 PL PL11805889T patent/PL2658573T3/pl unknown
- 2011-12-30 EP EP21158524.5A patent/EP3868397A1/en not_active Withdrawn
- 2011-12-30 CN CN201180063466.0A patent/CN103442731B/zh not_active Expired - Fee Related
- 2011-12-30 HU HUE11805889A patent/HUE053986T2/hu unknown
- 2011-12-30 PT PT118058890T patent/PT2658573T/pt unknown
- 2011-12-30 US US13/976,873 patent/US20140141042A1/en not_active Abandoned
-
2013
- 2013-05-23 IL IL226551A patent/IL226551B/en active IP Right Grant
-
2016
- 2016-03-11 US US15/068,115 patent/US20170049879A1/en not_active Abandoned
-
2017
- 2017-01-13 JP JP2017004556A patent/JP2017079787A/ja active Pending
- 2017-05-12 AU AU2017203189A patent/AU2017203189B2/en not_active Ceased
-
2020
- 2020-02-25 US US16/800,384 patent/US11701422B2/en active Active
-
2021
- 2021-05-17 CY CY20211100421T patent/CY1124146T1/el unknown
-
2023
- 2023-05-22 US US18/200,421 patent/US20240075125A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124146T1 (el) | Συστηματα εκφρασης | |
| CY1122800T1 (el) | Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων | |
| CL2023001338A1 (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
| CY1122691T1 (el) | Πρωτεϊνες δεσμευσης αλβουμινης ορου | |
| TR201908291T4 (tr) | Şifrelenmiş bir tümör antijeninin ekspresyonunun arttırılmasına yönelik bir histon sap-ilmiği ve bir poli(a) sekansı veya bir poliadenilasyon sinyali içeren veya bunun için kodlama yapan nükleik asit. | |
| BR112012029588A2 (pt) | materiais biológicas relacionados a her3. | |
| MX385926B (es) | Proteínas de fusión de citoquinas. | |
| CY1112924T1 (el) | Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης | |
| BR112013028407A2 (pt) | "sequências de aminoácido direcionadas em relação aos polipeptídeos de il-17a, il-17f e/ou il17-a/f compreendendo as mesmas, seus usos, polipeptídeos, e composição farmacêutica". | |
| AR114275A1 (es) | Anticuerpos anti-cd73 y métodos de uso de los mismos | |
| MX389093B (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| PY18107830A (es) | Variantes de alfa-amilasa y polinucleótidos que las codifican | |
| BR112019005587A2 (pt) | proteínas de ligação recombinantes e sua utilização | |
| CY1119276T1 (el) | Πολυπεπτιδια χλωροτοξινης και συζευγματα και χρησεις αυτων | |
| BR112019000195A2 (pt) | composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno | |
| CY1117162T1 (el) | Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης | |
| CY1120772T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| MX2023001119A (es) | Variantes de enzimas y polinucleotidos que las codifican. | |
| BR112018004965A2 (pt) | domínios de superfamìlia de imunoglobulina variante ajustàvel | |
| MX374682B (es) | Moléculas de unión a 4-1bb. | |
| CA2818969A1 (en) | Improved n-terminal capping modules for designed ankyrin repeat proteins | |
| BR112019012181A2 (pt) | enzimas polimerizantes para reações de sequenciamento | |
| ES2531290T3 (es) | Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas | |
| CO7010783A2 (es) | Proteína naglu humana recombinante y usos de la misma | |
| MX2017016610A (es) | Metodos de reduccion de olor. |